Mefloquine is not recommended for severe malaria infections, particularly infections from "P. falciparum", which should be treated with intravenous antimalarials. Mefloquine does not eliminate parasites in the liver phase of the disease, and people with "P. vivax" malaria should be treated with a second drug that is effective for the liver phase, such as primaquine. Mefloquine is widely used for the treatment of malaria in pregnancy. Limited data suggests that it is safe for this purpose. Resistance to mefloquine is now common around the west border in Cambodia and other parts of Southeast Asia. The mechanism of resistance is by increase
International Association for the Treatment of Sexual Offenders the context of their family, school, and other social systems in order to fully understand and decide the treatment and care for the juvenile. Another important element to keep in mind when choosing a treatment is to base it on a developmental perspective, which means it is sensitive to developmental change. This is necessary because during adolescence the brain is not fully developmental and is subjected to change. During assessment and treatment focus not only on the risks of the youths but also their strengths. Keep in mind that sexual interests of youth do change over adolescence and sexual orientation